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Objective: Hydatid disease occurs throughout the world and is treated with both surgery and
medical administration of albendazole. Some adverse effects of albendazole are known. However,
its genotoxic effect on humans has not been reported yet. In this study, we aimed to investigate the
genotoxic effect of albendazole on human lymphocytes in vivo.
Methods: The study involved 14 children (eight males and six females) who had undergone
operations for hepatic hydatid disease. The ages of the patients ranged from 6 to 13 years.
Genotoxicity of albendazole was evaluated as the frequency of sister chromatid exchange (SCE)
and micronucleated cells in the patient’s lymphocytes. Prior to and after albendazole treatment,
blood samples were obtained from these patients for SCE and micronucleus (MN) studies. SCE and
MN frequencies of the patients weremeasured separately before and after albendazole treatment.
Results: All patient SCE values increased significantly after albendazole administration
(p < 0.001). Similarly, MN frequencies in all the patients increased significantly following alben-
dazole treatment (p < 0.001).
Conclusion: This study revealed that both SCE and MN frequencies are higher after albendazole
treatment. The results suggest that albendazole may be genotoxic to human lymphocytes in vivo.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +90 442 2360817;
fax: +90 442 2360968.
E-mail address: sitkioztas@yahoo.com (S. Oztas).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.01.002Introduction
Human infection with Echinococcus occurs principally where
dogs are used to herd grazing animals, particularly sheep.Published by Elsevier Ltd. All rights reserved.
Genotoxic effect of albendazole in pediatric patients 447The adult worm is found in the small intestine of dogs,
wolves, and other canines. Human infection occurs when
eggs in dog feces are swallowed. The disease is common
throughout the world, particularly in the Mediterranean
littoral, Middle East, Central Asia, South America, and East
Africa. Hydatid disease is treated with both surgery and
medical administration of albendazole, which is effective
in eradication and prevention of recurrence.1—5
Albendazole is a benzimidazole. It is an antiparasitic agent
with a broad spectrum of activity against many helminthic
and certain protozoal infections. Albendazole has particu-
larly decreased morbidity and mortality rates in echinococ-
cosis in Echinococcus endemic countries.2,3,5—7
The antiparasitic activity of albendazole has been
described through its ability to bind with tubulin and cytos-
keletal proteins of parasites, thereby inhibiting the polymer-
ization of tubulin into microtubules. The disruption of
microtubule synthesis within parasitic intestinal cells results
in decreased absorptive function, rendering parasites unable
to reproduce and survive.6,7
After oral administration, albendazole is rapidly metabo-
lized in the liver. Its primary metabolite, albendazole sulf-
oxide, also has anthelmintic activity. Albendazole sulfoxide
has a half-life of approximately 9 hours. It is oxidized into
albendazole sulfone. The sulfone is an inactive form of
albendazole and is excreted in the urine.6,7
Some adverse effects of albendazole such as leukopenia,
pruritis, alopecia, gastric irritation, musculoskeletal pain,
and pancytopenia are known by clinicians. Nevertheless, its
genotoxic effect on the human genome has not yet been
reported.6—9
A large number of tests have been developed to evaluate
genetic damage. One of these tests, the sister chromatid
exchange (SCE) analysis, has been widely applied in genetic
toxicology studies. SCE represents the interchange of DNA
replication products at apparently homologous chromosomal
loci. These exchanges presumably involve DNA breakage and
reunion. Although the mechanism of SCE formation has not
been thoroughly elucidated, DNA damage and DNA-repair
defects play an important role in the formation of SCE.10—
12 SCE analysis has come into use as an indicator of response
to DNA damage. Various physical and chemical agents and
some idiopathic disorders have an increasing effect on fre-
quencies of SCE.12—18
The micronucleus (MN) frequency has also been used to
determine genotoxicity on the human genome. The MN
frequency is considered a direct indicator of numerical
and structural chromosome damage. MN can be formed
during mitosis through the loss of either whole chromosomes
or acentric chromosome fragments from the nucleus, which
are separate from the nucleus of the cell.7,16,19
This study aimed to investigate the genotoxic effect of
albendazole on SCE and MN formation in lymphocyte cultures
of pediatric patients with hydatid disease. To the best of our
knowledge, this is the first in vivo genotoxicity study on
albendazole exposure.
Methods
The study involved 14 children with hepatic hydatid disease.
The ages of the patients ranged from 6 to 13 years. Theirdiagnoses were established by ultrasonography and com-
puted tomography. Additionally, the Echinococcus hemagglu-
tination test was positive in all the patients.
All the patients had undergone operations for hydatid
cysts by pediatric surgeons. Preoperation, the patients
were given midazolam (0.05 mg/kg body weight) i.m. as
premedication. Anesthesia was induced with sodium thio-
pental (5—7 mg/kg body weight) and muscle relaxant atra-
curium (0.5 mg/kg body weight) and then maintained with
2—3% sevoflurane and oxygen/nitrous oxide (65/35%) mix-
ture.
Two weeks after the operation, each patient was treated
with albendazole (AndazolTM, Biofarma, Turkey) 15 mg/kg
p.o. daily (maximum 400 mg/dose) for 28 days. The course
is often repeated for four or more cycles, with 15-day drug-
free intervals.2,3,6
Before albendazole therapy, heparinized peripheral
venous blood samples were obtained from each patient for
SCE and MN studies. At the end of the first albendazole
treatment, blood samples of the patients were obtained
again for SCE and MN studies. None of the patients were
exposed to any physical or chemical agents except albenda-
zole during the study.
Peripheral blood samples were separately cultured for SCE
analysis and the MN test. For SCE analysis, the blood samples
were cultured for 72 hours at 37 8C in Chromosome Medium-B
(Biochrom) supplemented with L-glutamine (Biochrom) and
added 104 M 5-bromo-2-deoxyuridine (Sigma). Each culture
was maintained in total darkness to minimize photolysis of 5-
bromo-2-deoxyuridine. The harvest of cultures and chromo-
some preparations were conducted in line with routine
protocols.20 Bromodeoxyuridine-labelled metaphase chro-
mosomes were stained by the fluorescence plus Giemsa
technique as described by Wolff and Perry.21 A minimum of
30 satisfactory metaphase plaques per subject was scored for
SCE on coded slides by a single observer.
For the MN study, the blood samples were cultivated in
Chromosome Medium-B (Biochrom) supplemented with L-
glutamine (Biochrom) at 37 8C for 72 hours. Cytochalasin-B
(6 mg/ml, Sigma) was added at the 44th hour. The cultures
were harvested after 72 hours. The harvest of cultures and
MN preparations were conducted in line with standard pro-
tocols.19,22 The cells were carefully dropped onto cold micro-
scope slides to avoid membrane destruction, and incubated
at 37 8C or at room temperature overnight, and stained with
Giemsa dye.19,22 The coded slides were scored by a single
observer. Only binucleated cells were scored for MN analysis.
For each sample, at least 1000 binucleated cells (from 1050
to 2300) were analyzed for the presence of MN. MN criteria
described by Fenech et al. were used: the diameter less than
one-third of the main nucleus, separated from the main
nucleus, with similar color to the main nucleus.22 After MN
scoring, the frequency of micronuclei per 1000 cells was
calculated.
Statistical analysis
The SCE and MN results are expressed as the mean  SEM.
Values at different times in the same group were compared
by the Wilcoxon paired t-test. Values of p 0.05 were
considered statistically significant.
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Table 1 Patient sister chromatid exchange (SCE) data
Case no. Age Gender SCE frequency/cell
Before therapy After therapy
1 12 M 5.80  0.24 9.50  0.48
2 6 M 6.70  0.15 10.50  0.34
3 8 F 4.70  0.39 9.30  0.13
4 7 M 5.30  0.59 9.50  0.25
5 11 F 6.50  0.67 10.40  0.23
6 9 F 6.80  0.11 10.70  0.22
7 12 M 6.90  0.29 11.20  0.15
8 13 M 5.90  0.49 8.90  0.18
9 7 F 6.10  0.27 9.30  0.67
10 13 M 5.90  0.33 10.20  0.53
11 12 F 6.40  0.20 9.10  0.26
12 9 M 6.80  0.21 8.70  0.39
13 8 F 5.70  0.35 7.50  0.24
14 10 M 6.30  0.22 8.20  0.38
Mean  SEM 6.13  0.17 9.50  0.27
p Values p < 0.001Results
Fourteen children with hepatic hydatid disease (eight males
and six females) were included in the study. The age range of
the patients was 6 to 13 years (mean age: 9.79  0.63 years)
(Table 1). The mean SCE frequencies before and after alben-
dazole treatment were measured and compared. Before
albendazole administration, the mean SCE rate of the
patients was evaluated as the pretreatment control. The
mean SCE frequency of the control was 6.13  0.17. After
albendazole therapy, it was 9.50  0.27 (Table 1). The dif-
ference between SCE rates before and after albendazole
therapy was statistically significant ( p < 0.001).Table 2 Patient micronucleus (MN) data
Case no. Age Gender Before therapy
Cells scored Micronucle
Total
1 12 M 1420 3
2 6 M 1525 4
3 8 F 2010 3
4 7 M 1120 3
5 11 F 1480 5
6 9 F 2300 5
7 12 M 1230 2
8 13 M 1520 4
9 7 F 1600 5
10 13 M 1650 3
11 12 F 1280 3
12 9 M 1050 2
13 8 F 1750 3
14 10 M 1500 4
Mean  SEM
p ValuesMN frequency was measured and compared before and
after albendazole therapy. The number of MN was counted.
Before albendazole therapy, MN frequencies were evaluated
as the pretreatment control. Themean MN rate of the control
was 2.30  0.15. After albendazole therapy, it was
8.68  0.28 (Table 2). The difference between MN rates
before and after albendazole therapy was statistically sig-
nificant ( p < 0.001).
Discussion
The effectiveness of albendazole for the treatment and
prevention of hydatid disease is indisputable. Although some
side effects of albendazole are known, there have only been a
few studies on the genotoxic effects of albendazole.3,6—9
Ramirez et al. reported in vitro cytotoxic and genotoxic
effects of albendazole on human lymphocytes by using the
MN technique.7 In other studies, embryotoxic effects of
albendazole have been shown in rat models.8,9 In the litera-
ture, in vivo genotoxicity on the human genome has not yet
been reported. This study was based on SCE and MN fre-
quency analyses in order to investigate a possible relation-
ship between albendazole and genetic damage.
Albendazole inhibits microtubule formation during the
mitosis of parasites. Albendazole may also affect the genome
of the host cell.6,7 Its effect on the human genome can be
demonstrated by SCE analysis. In the present study, a statis-
tically significant difference in SCE rates was detected in the
comparison of the values before and after albendazole
administration ( p < 0.001) (Table 1). Our SCE results
revealed that albendazole may be a genotoxic agent on
the human genome.
Structural chromosomal aberrations or disturbed function
of the mitotic spindle may result in MN in the mitotic cells.
The MN assay is an effective test in the evaluation of the
effects of pharmacological, physical and chemicalAfter therapy
us Cells scored Micronucleus
Per 1000 cells Total Per 1000 cells
2.11 1350 11 8.15
2.62 1800 15 8.33
1.49 2200 17 7.73
2.68 1450 14 9.65
3.38 1320 14 10.61
2.17 1750 15 8.57
1.62 1650 12 7.27
2.63 1550 13 8.38
3.12 1680 18 10.71
1.82 2200 17 7.72
2.34 1340 12 8.95
1.90 1650 15 9.10
1.71 1650 13 7.88
2.67 2250 19 8.44
2.30  0.15 8.68  0.28
p < 0.001
Genotoxic effect of albendazole in pediatric patients 449agents.6,7,16,19,22 In this study, the MN rate increased after
albendazole therapy. The difference in MN rates was statis-
tically significant in the comparison of the values before and
after albendazole therapy ( p < 0.001) (Table 2). Therefore,
we suggest that albendazole may potentially be a genotoxic
agent for humans.
In this study, the possible effect of sevoflurane on the
patient’s genome was considered. Sevoflurane is an inhala-
tion anesthetic with characteristics suited for use in children.
The literature reveals a few studies that have investigated
the effect of sevoflurane on the human genome.23—26 Krause
et al. (2003) and Szyfter et al. (2004) reported that sevo-
flurane did not have any genotoxic effects on humans.23,24 In
contrast, Luleci et al. (2005) and Akin et al. (2005) have
shown a genotoxic effect of sevoflurane on humans by using
the SCE method. However, this effect was reversible, and the
frequency of SCE returned to normal levels within 5 to 12 days
after sevoflurane administration.25,26 Sevoflurane anesthesia
was administered to our patients. In order to eliminate the
possible genotoxic effects of sevoflurane, the first blood
samples were obtained at two weeks after the operations.
Our results demonstrated that exposure to albendazole
increased the frequencies of both SCE and micronucleated
cells. Thus, this drug may be a genotoxic agent as suggested
by the results of previous and present studies,7—9 and its
genotoxic effect should be kept in mind in treatment.
The results of the study indicate a genotoxic effect of
albendazole on lymphocytes in pediatric patients in vivo for
the first time. Further studies are needed to relate this
finding to a genotoxic risk assessment of albendazole admin-
istration.
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